Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Collapse authors list.
Duell, Johannes, Maddocks, Kami J, Gonzalez-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, de Vos, Sven, Nagy, Zsolt, Obr, Ales, Gaidano, Gianluca, Abrisqueta, Pau et al (show 11 more authors) , Kalakonda, Nagesh ORCID: 0000-0002-5300-1360, Andre, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet and Salles, Gilles (2021) Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. .

Access the full-text of this item by clicking on the Open Access link.

Item Type:	Conference or Workshop Item (Unspecified)
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	12 Jul 2021 09:44
Last Modified:	30 Jun 2022 03:17
DOI:	10.3324/haematol.2020.275958
Open Access URL:	https://doi.org/10.3324/haematol.2020.275958
Related URLs:	Author
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3129744